Botulinum toxin treatment for functional disability induced by essential tremor
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
This study aimed to improve botulinum toxin's (BTX) efficacy and to reduce its unwanted effects in the treatment of functional disability due to essential tremor (ET) of the hand. Twenty patients with disabling ET, not responding to conventional pharmacological therapy, were enrolled in this open-label study. Activities of daily living self-questionnaire (ADLS) and severity tremor scale (STS) were used to establish patients' functional disability and tremor severity. Accelerometry and surface electromyography were used to identify the arm muscles with tremorogenic activity during impaired positions. Global rating was used to measure treatment efficacy and unwanted effects. BTX type A was injected into the muscles principally responsible for impaired positions. After BTX treatment, there was a significant reduction in both severity and functional rating scales scores (ADLS and STS) and of tremor amplitude as measured with accelerometry and EMG. Adverse effects were limited to a slight third finger extension weakness in 15% of patients. BTX injections are effective and safe in reducing disability due to ET, if based on the criterion of functional selection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This approach has been used successfully with the advantage of providing very targeted relief (46–51).”
From Could Wearable and Mobile Technology Improve the Management of Essential Tremor? (2018) · cites this paper as [50]
Citations
Cites
Bain, P. G., Findley, L. J., Atchison, P., Behari, M., Vidailhet, M., Gresty, M., Rothwell, J. C., Thompson, P. D., & Marsden, C. D. (1993) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.56.8.868 · Cited by 437
Louis, E. D., Ottman, R., & Allen Hauser, W. (1998) · Movement Disorders · doi:10.1002/mds.870130105 · Cited by 424 · cited 1×
“Only 50%-60% of patients with ET, the most common movement disorder [14], improves functional disability pharmacologically.”
BackgroundJankovic, J., Schwartz, K., Clemence, W., Aswad, A., & Mordaunt, J. (1996) · Movement Disorders · doi:10.1002/mds.870110306 · Cited by 235 · cited 4×
“The use of botulinum toxin type A (BTX) for the treatment of hand tremor has now been established [1-5].”
BackgroundMethodInfluentialBotulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system.
Girlanda, P., Vita, G., Nicolosi, C., Milone, S., & Messina, C. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.9.844 · Cited by 184
Advances in processing of surface myoelectric signals: Part 1
Merletti, R., & Conte, L. L. (1995) · Medical & Biological Engineering & Computing · doi:10.1007/bf02510518 · Cited by 158
Botulinum toxin treatment of tremors
Jankovic, J., & Schwartz, K. (1991) · Neurology · doi:10.1212/wnl.41.8.1185 · Cited by 152
“Off” painful dystonia in Parkinson's disease treated with botulinum toxin
Pacchetti, C., Albani, G., Martignoni, E., Godi, L., Alfonsi, E., & Nappi, G. (1995) · Movement Disorders · doi:10.1002/mds.870100317 · Cited by 116
Self-citationBotulinum toxin a injections for the treatment of hand tremors
Trosch, R. M., & Pullman, S. L. (1994) · Movement Disorders · doi:10.1002/mds.870090604 · Cited by 111
Pharmacologic treatment of essential tremor.
Koller, W. C., Hristova, A. H., & Brin, M. F. (2000) · PubMed · Cited by 79
Advances in processing of surface myoelectric signals: Part 2
Conte, L. L., & Merletti, R. (1995) · Medical & Biological Engineering & Computing · doi:10.1007/bf02510519 · Cited by 59
Cited by
Essential tremor: diagnosis and management
Shanker, V. (2019) · BMJ · doi:10.1136/bmj.l4485 · Cited by 182
Botulinum Toxin in Movement Disorders: An Update
Anandan, C., & Jankovic, J. J. (2021) · Toxins · doi:10.3390/toxins13010042 · Cited by 171
Benefits and Risks of Pharmacological Treatments for Essential Tremor
Lyons, K. E., Pahwa, R., Comella, C. L., Eisa, M. S., Elble, R. J., Fahn, S., Jankovic, J., Juncos, J. L., Koller, W. C., Ondo, W. G., et al. (2003) · Drug Safety · doi:10.2165/00002018-200326070-00003 · Cited by 103
Zappia, M., Albanese, A., Bruno, E., Colosimo, C., Filippini, G., Martinelli, P., Nicoletti, A. S. Q., Quattrocchi, G., Abbruzzese, G., Berardelli, A., et al. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6628-x · Cited by 100
Botulinum Toxin in Parkinson Disease Tremor
Mittal, S. O., Machado, D., Richardson, D., Dubey, D., & Jabbari, B. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.06.010 · Cited by 72
Botulinum toxins in neurological disease
Comella, C., & Pullman, S. L. (2004) · Muscle & Nerve · doi:10.1002/mus.20033 · Cited by 69
Treatment of essential tremor: current status
Sharma, S., & Pandey, S. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136647 · Cited by 66
Botulinum Toxin for the Treatment of Hand Tremor
Niemann, N., & Jankovic, J. J. (2018) · Toxins · doi:10.3390/toxins10070299 · Cited by 57
Botulinum toxin for the treatment of tremor
Mittal, S. O., Lenka, A., & Jankovic, J. J. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.01.023 · Cited by 60
Rahimi, F., Samotus, O., Lee, J., & Jog, M. (2015) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.240 · Cited by 55
Samotus, O., Rahimi, F., Lee, J., & Jog, M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153739 · Cited by 46
“Preliminary work shows that identification of tremulous joints and muscles by accelerometers and by surface EMG can reduce the occurrence of muscle weakness [11].”
BackgroundMethodInfluentialCurrent and Future Neuropharmacological Options for the Treatment of Essential Tremor
Alonso‐Navarro, H., García‐Martín, E., Agúndez, J. A. G., & Jiménez‐Jiménez, F. J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200124145743 · Cited by 39
Symptomatic and Disease-Modifying Therapy for the Progressive Ataxias
Perlman, S. (2004) · The Neurologist · doi:10.1097/01.nrl.0000141651.35193.67 · Cited by 44
Use of botulinum toxin for movement disorders
Camargo, C. H. F., & Teive, H. A. G. (2019) · Drugs in Context · doi:10.7573/dic.212586 · Cited by 34
Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics
Samotus, O., Kumar, N., Rizek, P., & Jog, M. (2017) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2017.260 · Cited by 34
Essential tremor: Treatment options
Ondo, W. G. (2006) · Current Treatment Options in Neurology · doi:10.1007/s11940-006-0016-8 · Cited by 28
Keller, S. R., & Dure, L. S. (2009) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2009.03.007 · Cited by 26
The Fragile X-Associated Tremor Ataxia Syndrome (FXTAS)
Tassone, F., & Berry‐Kravis, E. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5805-1 · Cited by 31
Botulinum toxin in management of limb tremor
Zakin, E., & Simpson, D. (2017) · Toxins · doi:10.3390/toxins9110365 · Cited by 23
Could Wearable and Mobile Technology Improve the Management of Essential Tremor?
Daneault, J.-F. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00257 · Cited by 21
Singer, C., Papapetropoulos, S., & Spielholz, N. I. (2005) · Movement Disorders · doi:10.1002/mds.20590 · Cited by 17
Dynamic Decomposition of Motion in Essential and Parkinsonian Tremor
Rahimi, F., Debicki, D., Roberts, A., Bee, C., Bapat, P., & Jog, M. (2015) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2015.12 · Cited by 16
Pharmacological treatment of disabling tremor
Schadt, C. R., Duffis, E. I., & Charles, D. P. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.3.419 · Cited by 15
NEUROTOXIN INJECTION FOR MOVEMENT DISORDERS
Charles, D. P., & Gill, C. E. (2010) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000348904.32834.70 · Cited by 13
Treatment and Management of FXTAS
Berry‐Kravis, E., Hall, D. A., Leehey, M. A., & Hagerman, R. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5805-1_9 · Cited by 13
Kreisler, A., Bouchain, B., Defebvre, L., & Krystkowiak, P. C. (2019) · Tremor and Other Hyperkinetic Movements · doi:10.7916/d8-39fg-qs60 · Cited by 14
Samotus, O., Lee, J., & Jog, M. (2021) · Toxins · doi:10.3390/toxins13040264 · Cited by 10
Chapter 41 Focal injection therapy
Graciès, J., & Simpson, D. M. (2003) · Handbook of clinical neurophysiology · doi:10.1016/s1567-4231(09)70189-3 · Cited by 8
Treatment and management issues in ataxic diseases
Perlman, S. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-51892-7.00046-2 · Cited by 9
Use of Botulinum Toxin in Upper-Limb Tremor: Systematic Review and Perspectives
Motavasseli, D., Delorme, C., Bayle, N., Graciès, J., Roze, E. F., & Baude, M. (2024) · Toxins · doi:10.3390/toxins16090392 · Cited by 7
Botulinum Toxins: Transformation of a Toxin into a Treatment
Cornelia, C. L., Simpson, L. L., & Jankovic, J. J. (2005) · Elsevier eBooks · doi:10.1016/b978-012738903-5/50008-4 · Cited by 6
Tratamiento del temblor esencial
Velasco, P. E. B. (2007) · Medicina Clínica · doi:10.1157/13107921 · Cited by 4
Botulinum toxin for essential tremor
Gulati, K., & Pandey, S. (2025) · Toxicon · doi:10.1016/j.toxicon.2025.108273 · Cited by 3
Botulinum Toxin for the Treatment of Tremors
Bellows, S. T., & Jankovic, J. J. (2025) · Toxins · doi:10.3390/toxins17080401 · Cited by 2
The use of botulinum neurotoxin in tic disorders and essential hand and head tremor
Jankovic, J. J. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139178068.019 · Cited by 2
The role of botulinum toxin (type A) in the management of spastic stroke patients
El-Tamawy, M., Abdel-Kader, A., Shereen, F., Hatem, S., Abokrysha, N. T., El-Bahrawy, M. N., & Darwish, M. H. (2005) · Revue Neurologique · doi:10.1016/s0035-3787(05)85233-6 · Cited by 2
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00018-4 · Cited by 2
Essential Tremor: Symptoms and Treatment
Wick, J. Y., & Zanni, G. R. (2008) · The Consultant Pharmacist · doi:10.4140/tcp.n.2008.364 · Cited by 2
Botulinum Toxin Efficacy in Upper Limb Tremor: A Systematic Review and Meta‐Analysis
Visser, I. M., Pitakpatapee, Y., van de Warrenburg, B. P. C., Helmich, R. C. G., Snijders, A. H., & Nijhuis, F. A. P. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70307 · Cited by 1
Emerging Therapies for the Treatment of Essential Tremor
Shill, H. A. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2196 · Cited by 1
Other clinical neurological uses of botulinum toxin
Barnes, M. P. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544842.016
Medical Treatment of Essential Tremor
Pahwa, A. (2005) · Neurological disease and therapy · doi:10.1201/b14115-12
Fekete, R., Jankovic, J. J., Shill, H. A., Evidente, V. G. H., & Gwinn, K. A. (2014) · Wiley eBooks · doi:10.1002/9781118730676.ch12
Evidence-Based Review of Current Botulinum Toxin Treatment Indications in Medicine
Vijayakumar, D., & Jankovic, J. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-50691-9_4 · Cited by 1
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00010-x
Charles, D. P., & Gill, C. E. (2012) · Informa Healthcare eBooks · doi:10.3109/9781841848525.027
Asadi, B., Hassani, S., Ghanaati, H., Rahmatian, A., Azami, M., & Gheshlaghi, S. A. (2023) · Neurology Letters · doi:10.61186/nl.2.2.69
Botulinum Neurotoxin Treatment Outcomes for Upper Limb Tremors: A Literature Review
Sankar, K., Subairdeen, M. A., Muthukrishnan, N. K., Samhan, A. A. A., & Giri, J. P. (2025) · Studies in systems, decision and control · doi:10.1007/978-3-031-89771-9_94
Mélançon, K. (2021) · Corpus Université Laval (Université Laval)
Metadata
- Authors
- Pacchetti, C., Mancini, F., Bulgheroni, M., Zangaglia, R., Cristina, S., Sandrini, G., & Nappi, G.
- Affiliations
- University of Pavia (IT)
- Sapienza University of Rome (IT)
- Venue
- Neurological Sciences
- Published
- 2000-12-01
- Volume
- 21
- Issue
- 6
- Pages
- 349-353
- ISSN
- 1590-1874 (ISSN-L)
- 1590-3478
- OpenAlex
- W2022514226
- Cited by
- 48
- References
- 11
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 1 · 2021: 3 · 2020: 2 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 2 · 2012: 2
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neurological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Keywords
- botulinum toxin type A, essential tremor, hand tremor, functional disability, activities of daily living, tremor severity, surface electromyography, accelerometry, adverse effects, treatment efficacy
- MeSH terms
- Aged, Arm, Disability Evaluation, Electromyography, Female, Humans, Male, Middle Aged, Neuromuscular Agents, Surveys and Questionnaires, Treatment Outcome, Patient Satisfaction, Muscle, Skeletal, Botulinum Toxins, Type A, Recovery of Function, Essential Tremor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.